185 related articles for article (PubMed ID: 33421628)
21. Therapeutic drug monitoring of anti-TNF drugs: an overview of applicability in daily clinical practice in the era of treatment with biologics in juvenile idiopathic arthritis (JIA).
Nassar-Sheikh Rashid A; Schonenberg-Meinema D; Bergkamp SC; Bakhlakh S; de Vries A; Rispens T; Kuijpers TW; Wolbink G; van den Berg JM
Pediatr Rheumatol Online J; 2021 Apr; 19(1):59. PubMed ID: 33926495
[TBL] [Abstract][Full Text] [Related]
22. Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease.
Pallagi-Kunstár É; Farkas K; Szepes Z; Nagy F; Szűcs M; Kui R; Gyulai R; Bálint A; Wittmann T; Molnár T
World J Gastroenterol; 2014 May; 20(17):5031-5. PubMed ID: 24833846
[TBL] [Abstract][Full Text] [Related]
23. Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients.
Colman RJ; Portocarrero-Castillo A; Chona D; Hellmann J; Minar P; Rosen MJ
Inflamm Bowel Dis; 2021 Mar; 27(4):507-515. PubMed ID: 32426829
[TBL] [Abstract][Full Text] [Related]
24. An Indian national survey of therapeutic drug monitoring with anti-tumor necrosis (TNF) medications in inflammatory bowel disease.
Patel RN; Nigam GB; Jatale RG; Desai D; Makharia G; Ahuja V; Limdi JK
Indian J Gastroenterol; 2020 Apr; 39(2):176-185. PubMed ID: 32483692
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease.
Franca R; Curci D; Lucafò M; Decorti G; Stocco G
Expert Opin Drug Metab Toxicol; 2019 Jul; 15(7):527-539. PubMed ID: 31177858
[No Abstract] [Full Text] [Related]
26. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M
Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
[TBL] [Abstract][Full Text] [Related]
27. Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
Syversen SW; Jørgensen KK; Goll GL; Brun MK; Sandanger Ø; Bjørlykke KH; Sexton J; Olsen IC; Gehin JE; Warren DJ; Klaasen RA; Noraberg G; Bruun TJ; Dotterud CK; Ljoså MKA; Haugen AJ; Njålla RJ; Zettel C; Ystrøm CM; Bragnes YH; Skorpe S; Thune T; Seeberg KA; Michelsen B; Blomgren IM; Strand EK; Mielnik P; Torp R; Mørk C; Kvien TK; Jahnsen J; Bolstad N; Haavardsholm EA
JAMA; 2021 Dec; 326(23):2375-2384. PubMed ID: 34932077
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease.
Battat R; Lukin D; Scherl EJ; Pola S; Kumar A; Okada L; Yang L; Jain A; Siegel CA
Inflamm Bowel Dis; 2021 Aug; 27(9):1443-1451. PubMed ID: 33252119
[TBL] [Abstract][Full Text] [Related]
29. Advantages of Proactive Therapeutic Drug Monitoring in a Prospective Cohort of Children With Inflammatory Bowel Disease Treated With Anti-Tumour Necrosis Factor.
Gasparetto M; Burgess N; Naik S; Studart D; Kadir A; Croft N; Sanderson I; Deb P
J Pediatr Gastroenterol Nutr; 2022 Apr; 74(4):484-489. PubMed ID: 35129158
[TBL] [Abstract][Full Text] [Related]
30. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease.
Strik AS; van den Brink GR; Ponsioen C; Mathot R; Löwenberg M; D'Haens GR
Aliment Pharmacol Ther; 2017 Apr; 45(8):1128-1134. PubMed ID: 28230306
[TBL] [Abstract][Full Text] [Related]
31. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD.
Frederiksen MT; Ainsworth MA; Brynskov J; Thomsen OO; Bendtzen K; Steenholdt C
Inflamm Bowel Dis; 2014 Oct; 20(10):1714-21. PubMed ID: 25069030
[TBL] [Abstract][Full Text] [Related]
32. Clinically important neutralizing anti-drug antibodies detected with an in-house competitive ELISA.
Ogrič M; Žigon P; Lakota K; Praprotnik S; Drobne D; Štabuc B; Sodin-Semrl S; Čučnik S
Clin Rheumatol; 2019 Feb; 38(2):361-370. PubMed ID: 30014359
[TBL] [Abstract][Full Text] [Related]
33. Monitoring of infliximab trough levels and anti-infliximab antibodies in inflammatory bowel diseases: A comparison of three commercially available ELISA kits.
Bertin D; Serrero M; Grimaud JC; Desjeux A; Desplat-Jégo S
Cytokine; 2020 Feb; 126():154859. PubMed ID: 31629989
[TBL] [Abstract][Full Text] [Related]
34. A Systematic Review on Infliximab and Adalimumab Drug Monitoring: Levels, Clinical Outcomes and Assays.
Silva-Ferreira F; Afonso J; Pinto-Lopes P; Magro F
Inflamm Bowel Dis; 2016 Sep; 22(9):2289-301. PubMed ID: 27508512
[TBL] [Abstract][Full Text] [Related]
35. Strategies for overcoming anti-tumor necrosis factor drug antibodies in inflammatory bowel disease: Case series and review of literature.
Kothari MM; Nguyen DL; Parekh NK
World J Gastrointest Pharmacol Ther; 2017 Aug; 8(3):155-161. PubMed ID: 28828193
[TBL] [Abstract][Full Text] [Related]
36. Early detection of anti-drug antibodies during initiation of anti-tumour necrosis factor therapy predicts treatment discontinuation in inflammatory bowel disease.
Tournier Q; Paul S; Williet N; Berger AE; Veyrard P; Boschetti G; Le Roy B; Killian M; Phelip JM; Flourie B; Nancey S; Roblin X
Aliment Pharmacol Ther; 2021 Jun; 53(11):1190-1200. PubMed ID: 33872404
[TBL] [Abstract][Full Text] [Related]
37. A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease.
Billiet T; Dreesen E; Cleynen I; Wollants WJ; Ferrante M; Van Assche G; Gils A; Vermeire S
Am J Gastroenterol; 2016 Oct; 111(10):1438-1445. PubMed ID: 27481307
[TBL] [Abstract][Full Text] [Related]
38. One year of experience with combined pharmacokinetic/pharmacogenetic monitoring of anti-TNF alpha agents: a retrospective study.
Cheli S; Savino D; De Silvestri A; Norsa L; Sansotta N; Penagini F; Dilillo D; Panceri R; Cattaneo D; Clementi E; Zuin G
Pharmacogenomics J; 2023 Sep; 23(5):112-118. PubMed ID: 37016150
[TBL] [Abstract][Full Text] [Related]
39. Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease.
Gil-Candel M; Gascón-Cánovas JJ; Urbieta-Sanz E; Rentero-Redondo L; Onteniente-Candela M; Iniesta-Navalón C
Int J Clin Pharm; 2020 Apr; 42(2):500-507. PubMed ID: 32006141
[TBL] [Abstract][Full Text] [Related]
40. Comparison of 3 Enzyme-Linked Immunoassay Methods to Evaluate Serum Concentrations of Infliximab and Antibodies to Infliximab in 32 Patients with Moderate to Severe Inflammatory Bowel Disease.
Jukic T; Drobne D; Pusavec S; Ihan A; Stubljar D; Starc A
Med Sci Monit; 2023 Feb; 29():e939084. PubMed ID: 36807319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
